Structure and Anti-HIV Activity of Betulinic Acid Analogues

Abstract

Firstly discovered in 1980s, human immunodeficiency virus (HIV) continues to affect more and more people. However, there is no effective drug available for the therapy of HIV infection. Betulinic acid existing in various medicinal herbs and fruits exhibits multiple biological effects, especially its outstanding anti-HIV activity, which has drawn the attentions of many pharmacists. Among the derivatives of betulinic acid, some compounds exhibited inhibitory activities at the nanomolar concentration, and have entered phase II clinical trials. This paper summarizes the current investigations on the anti-HIV activity of betulinic acid analogues, and provides valuable data for subsequent researches.

Keywords

betulinic acid analogues / HIV / structural modification / structure activity relationship

References

[1] ArtsEJ, HazudaDJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med, 2012, 2: a007161

[2] TangMW, ShaferRW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs, 2012, 72(9): el-25

[3] ZhanP, PannecouqueC D, ClercqE, et al.. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. J Med Chem, 2016, 59(7): 2849-2878

[4] IyidoganP, AndersonKS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses, 2014, 6(10): 4095-4139

[5] CraggGM, GrothausPG, NewmanDJ. Impact of natural products on developing new anti-cancer agents. Chem Rev, 2009, 109(7): 3012-3043

[6] KuttanG, PratheeshkumarP, ManuKA, et al.. Inhibition of tumor progression by naturally occurring terpenoids. Pharm Biol, 2011, 49(10): 995-1007

[7] FuldaS. Betulinic Acid for cancer treatment and prevention. Int J Mol Sci, 2008, 9(6): 1096-1107

[8] AlakurttiS, MakelaT, KoskimiesS, et al.. Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci, 2006, 29(1): 1-13

[9] GuptaN, RathSK, SinghJ, et al.. Synthesis of novel benzylidene analogues of betulinic acid as potent cytotoxic agents. Eur J Med Chem, 2017, 135: 517-530

[10] DangrooNA, SinghJ, RathSK, et al.. A convergent synthesis of novel alkyne-azide cycloaddition congeners of betulinic acid as potent cytotoxic agent. Steroids, 2017, 123: 1-12

[11] MartinDE, BlumR, WiltonJ, et al.. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother, 2007, 51(9): 3063-3066

[12] AltmannKH. Semisynthetic derivatives of epothilones. Fortschr Chem Org Naturst, 2009, 90: 135-156

[13] LiF, Goila-GaurR, SalzwedelK, et al.. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA., 2003, 100(23): 13555-13560

[14] LiF R, Goila-GaurK, SalzwedelNR, et al.. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci, 2003, 100: 13555-13560

[15] SmithPF, OgundeleA, ForrestA, et al.. Phase I and II study of the safety, virologie effect, and pharmacokinetics/pharmacodynamics of singledose 3-o-(3',3'-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother, 2007, 51(10): 3574-3581

[16] MartinDE, BlumR, DotoJ, et al.. Multiple-dose pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin Pharmacokinet, 2007, 46(7): 589-598

[17] LaiW, HuangL, HoP, et al.. Betulinic acid derivatives that target gpl20 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2008, 52(1): 128-136

[18] MayauxJF, BousseauA, PauwelsR, et al.. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci USA, 1994, 91(9): 3564-3568

[19] YuanX, HuangL, HoP, et al.. Conformation of gpl20 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. Virology, 2004, 324(2): 525-530

[20] DangZ, HoP, ZhuL, et al.. New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. J Med Chem, 2013, 56(5): 2029-2037

[21] DangZ, QianK, HoP, et al.. Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants. Bioorg Med Chem Lett, 2012, 22(16): 5190-5194

[22] QianK, BoriID, ChenCH, et al.. Anti-AIDS agents 90. Novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors. J Med Chem, 2012, 55(18): 8128-8136

[23] UranoE, AblanSD, MandtR, et al.. Alkyl amine bevirimat derivatives are potent and broadly active HIV-1 maturation inhibitors. Antimicrob Agents Chemother, 2015, 60(1): 190-197

[24] TimilsinaU, GhimireD, TimalsinaB, et al.. Identification of potent maturation inhibitors against HIV-1 clade C. Sci Rep, 2016, 6: 27403

[25] HuangL, HoP, LeeKH, et al.. Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives. Bioorg Med Chem, 2006, 14(7): 2279-2289

[26] HuangL, YuanX, AikenC, et al.. Bifimctional antihuman immunodeficiency virus type 1 small molecules with two novel mechanisms of action. Antimicrob Agents Chemother, 2004, 48(2): 66366-66275

[27] ZimmermannGR, LehárJ, KeithCT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today, 2007, 12: 34-42

[28] MorphyR, KayC, RankovicZ. From magic bullets to designed multiple ligands. Drug Discov Today, 2004, 9: 641-651

[29] XiongJ, KashiwadaY, ChenCH, et al.. Conjugates of betulin derivatives with AZT as potent anti-HIV agents. Bioorg Med Chem, 2010, 18(17): 6451-6469

[30] BoriID, HungHY, QianK, et al.. Anti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistry. Tetrahedron Lett, 2012, 53(15): 1987-1989

[31] WangP, LiuC, SanchesT, et al.. Design and synthesis of novel nitrogen-containing polyhydroxylated aromatics as HIV-l integrase inhibitors from caffeic acid phenethyl ester. Bioorg Med Chem Lett, 2009, 19(16): 4574-4578

[32] ZhaoY, GuQ, Morris-NatschkeSL, et al.. Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-l. J Med Chem, 2016, 59(19): 9262-9268

[33] CoricP, TurcaudS, SouquetF, et al.. Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem, 2013, 62: 453-465

[34] GonzalezG, DaFonsecaS, ErrazurizE, et al.. Characterization of a novel type of HIV-l particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assay. PLoS One, 2011, 6(11): e27234

[35] ZhaoH, HolmesSS, BakerGA, et al.. Ionic derivatives of betulinic acid as novel HIV-l protease inhibitors. J Enzyme Inhib Med Chem, 2012, 27(5): 715-721

[36] SwidorskiJJ, LiuZ, SitSY, et al.. Inhibitors of HIV-1 maturation: Development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids. Bioorg Med Chem Lett, 2016, 26(8): 1925-1930

[37] Nowicka-SansB, ProtackT, LinZ, et al.. Identification and characterization of BMS-955176, a secondgeneration HIV-l maturation inhibitor with improved potency, antiviral spectrum, and gag polymorphic coverage. Antimicrob Agents Chemother, 2016, 60(7): 3956-3969

[38] QianK, Nakagawa-GotoK, YuD, et al.. Anti-AIDS agents 73: structure-activity relationship study and asymmetric synthesis of 3-O-monomethylsuccinylbetulinic acid derivatives. Bioorg Med Chem Lett, 2007, 17(23): 6553-6557

[39] QianK, KuoRY, ChenCH, et al.. Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. J Med Chem, 2010, 53(8): 3133-3141

[40] LiuZ, SwidorskiJJ, Nowicka-SansB, et al.. C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-l maturation inhibitors. Bioorg Med Chem, 2016, 24(8): 1757-1770

[41] TangJ, JonesSA, JefferyJL, et al.. Synthesis and biological evaluation of macrocyclized betulin derivatives as a novel class of anti-HIV-1 maturation inhibitors. Open Med Chem J, 2014, 8: 23-27

[42] LiJ, GotoM, YangX, et al.. Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity. Bioorg Med Chem Lett, 2016, 26(1): 68-71

[43] TangJ, JonesSA, JeffreyJL, et al.. Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms. Bioorg Med Chem Lett, 2017, 27(12): 2689-2694